Pioneering molecular diagnostics company MI:RNA, which uses biomarkers and advanced modelling to diagnose veterinary disease earlier, has reached a growth milestone with the completion of an oversubscribed funding round.
The conclusion of this second Venture Capital (VC) led financing, which has raised $3.6 million, accelerates a rapid period of expansion and commercial progress for the company, as it advances its mission to bring faster, more accurate, and more accessible diagnostic solutions to veterinarians, producers, and animal health professionals worldwide.
Having achieved a $4 million Series A funding rounding in July 2024, the recent round attracted strong participation from existing investors, reflecting confidence in the company’s early disease detection technology, commercial strategy, and international presence, partnering with lab networks in the UK and the EU. The company was also pleased to onboard two new investment funds bringing an added breadth of expertise to the table.
Eve Hanks, CEO and founder, said: “Our technology uses biomarkers and advanced modelling to spot health problems in animals earlier than ever before with a simple blood sample. With this incredible new approach, we can diagnose, monitor, and predict how diseases will develop for happier, healthier pets and a sustainable future for agriculture.
“The opportunity to deploy our diagnostic platform globally through our partner laboratories is taking shape, and this positive support from our investors not only validates the strength of our technology
and market approach, it also accelerates our continued development and technological advancement as we work to bring critical diagnostic solutions into the hands of those who need them most.
“This is a positive milestone for us that will allow us to scale more quickly, as we work to give animals longer, healthier lives.”
Funds have been raised from existing investors including NovaQuest, Kyoritsu Holdings Corporation, VANE (Angel Syndicate), Animal Health Angels, Equity Gap, Gabriel, Scottish Enterprise, as well as new investors Holstein UKand AniVC.
Brian Axe, Partner at NovaQuest Capital Management said: “The continued overwhelming support of MI:RNA is a testament to the promise of this company, the team, and this innovative platform. We are excited to see this technology deployed in the market.”
With global demand for efficient, data-driven and precise diagnostic solutions continuing to climb, MI:RNA is positioned to play a pivotal role in reshaping the future of livestock and companion animal care.
Expansion into America has been a huge success, with the opening of a new research lab facility at the University of Georgia in Athens last year. This has led to an expansion of development and validation work with even more collaborators.
MI:RNA has grown to a team of 36 workers across the UK, EU, APAC and the US. Alongside welcoming new Chief Veterinary Officer, Dr Natalie Marks, in October, MI:RNA has also appointed Chief Operating Officer, Rose Jenkins, who will join in January 2026. Rose has over 25 years of strategic and operational leadership across complex public and private sector organisations and will guide MI:RNA in its ambition to move towards a fully commercialised offering
The funding will be used to accelerate commercial growth in partnership with key multinationals in animal health, as MI:RNA further advances its flagship diagnostic platform, and delivers impact for people, animals and planet.